222. Primary nephrotic syndrome Clinical trials / Disease details
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03649152 (ClinicalTrials.gov) | November 8, 2018 | 7/8/2018 | Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan | A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving Irbesartan | Focal Segmental Glomerulosclerosis | Drug: Propagermanium;Drug: Placebo | Dimerix Bioscience Pty Ltd | Iqvia Pty Ltd | Active, not recruiting | 18 Years | 80 Years | All | 10 | Phase 2 | Australia |